Physician profile
Clay E Beveridge
NPI 1407807431
$2,072.86
in general payments reported to CMS, 2019-2025
36 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $522 · 2021: $230 · 2022: $527 · 2023: $138 · 2024: $341 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $284.86 | 2020-2025 | |
| Amgen INC. | $267.20 | 2020-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $186.93 | 2021-2025 | Ubrelvy |
| Medicure Pharma INC. | $178.96 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $127.52 | 2020-2025 | Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $97.59 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.89 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $59.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.52 | 2020-2021 | |
| Boston Scientific Corporation | $54.93 | 2024-2025 | Bodyguardian |
| Lilly USA, LLC | $49.96 | 2020-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $49.63 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $47.88 | 2023-2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $43.57 | 2022 | |
| Eisai INC. | $41.18 | 2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Beveridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.